These engagers can be composed of a TCR or TCR-like domain that binds to a neoantigen-HLA complex and a domain that binds to CD3, thereby stimulating and redirecting CD8 as well CD4 T cell reactivity towards tumor cells (48). The gene discussed is CD8A; the disease is neoplasm.